<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.ajmc.com/view/ai-s-promise-in-ophthalmology-comes-with-responsibilities-ravi-d-goel-md</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/bfc607b652dd597c6c6af08cca650c0ecf8735d3-1200x640.png</video:thumbnail_loc><video:title><![CDATA[ AI’s Promise in Ophthalmology Comes With Responsibilities: Ravi D. Goel, MD]]></video:title><video:description><![CDATA[Ambient AI and analytics may ease clinical workloads and uncover insights, but safety, validated data, HIPAA compliance, and equity must guide adoption.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407194638112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/reaching-people-who-use-drugs-to-end-hcv-norah-terrault-md-mph</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3915808d4c097cb3294ffc2e94331918e59f7780-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Reaching People Who Use Drugs to End HCV: Norah Terrault, MD, MPH]]></video:title><video:description><![CDATA[Immediate DAA treatment, syringe services, and society advocacy are key to eliminating the hepatitis C virus (HCV) among people who use drugs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407192290112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/oveporexton-treats-root-cause-of-narcolepsy-type-1-saema-tahir-md</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ad2f47e55de6d1ec078087cf81c1bb4c50a961b4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Oveporexton Treats Root Cause of Narcolepsy Type 1: Saema Tahir, MD]]></video:title><video:description><![CDATA[Saema Tahir, MD, says oveporexton targets the root cause of narcolepsy type 1, but adverse effects and access barriers will need close management.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407146258112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-ai-can-improve-cancer-care-access-quality-johnetta-blakely-md</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/029ad7712ef00ff7c9c22a0cbf63c9c8a12047de-1200x640.png</video:thumbnail_loc><video:title><![CDATA[How AI Can Improve Cancer Care Access, Quality: Johnetta Blakely, MD]]></video:title><video:description><![CDATA[Tennessee Oncology’s Johnetta Blakely, MD, MS, discusses how AI could ease workforce strain, support quality tracking, and the barriers to adopting it.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406555253112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/real-time-data-to-drive-cancer-pathways-edward-arrowsmith-md-mph</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2f8e00d3e89a54e48da9ef0d587123133d0e0dd0-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Real-Time Data to Drive Cancer Pathways: Edward Arrowsmith, MD, MPH]]></video:title><video:description><![CDATA[OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how pathways keep pace with new approvals and why real-time data will shape their future.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406314481112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/making-the-case-for-earlier-lems-screening-to-payers</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Making the Case for Earlier LEMS Screening to Payers]]></video:title><video:description><![CDATA[A better prognosis, randomized evidence of treatment benefit, and a genuinely rare patient population combine into a compelling pitch for prioritizing LEMS screening and access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635891112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/limited-stage-sclc-unmet-needs-and-emerging-biomarkers</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[Limited-Stage SCLC: Unmet Needs and Emerging Biomarkers]]></video:title><video:description><![CDATA[Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406921565112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/is-the-11-micromolar-threshold-right-for-aatd-augmentation</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Is the 11 Micromolar Threshold Right for AATD Augmentation?]]></video:title><video:description><![CDATA[The 11 micromolar target was built on epidemiologic reasoning rather than a normal range. Pending trials of higher doses and longer-acting agents may show whether raising levels further improves outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405745111112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/patient-and-practice-level-barriers-in-limited-stage-sclc-care</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[Patient and Practice-Level Barriers in Limited-Stage SCLC Care]]></video:title><video:description><![CDATA[Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406923329112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/formulary-strategy-and-the-evidence-gaps-still-facing-mdd-add-on-therapy</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/fd4287878e1ed18857995e5614198afcc8d2311f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Formulary Strategy and the Evidence Gaps Still Facing MDD Add-On Therapy]]></video:title><video:description><![CDATA[Looking ahead, Dr. Citrome weighs how payers should structure formulary access today against the long-term evidence still missing on treatment duration and relapse risk.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405498651112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/plasma-derived-augmentation-therapy-for-aatd-products-and-access</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Plasma-Derived Augmentation Therapy for AATD: Products and Access]]></video:title><video:description><![CDATA[Four plasma-derived products deliver the same purified protein and appear clinically interchangeable. Differences in formulation, administration, and coverage design shape which product a patient actually receives.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405745110112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-group-purchasing-organizations-affect-access-to-lems-therapy</loc><video:video><video:publication_date>2026-10-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Group Purchasing Organizations Affect Access to LEMS Therapy]]></video:title><video:description><![CDATA[Group purchasing organizations shape drug access for most community oncology practices, and amifampridine's unusual profile leaves open questions about how that relationship will function.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636782112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/administrative-burden-keeps-clinicians-from-bedside-amy-morris-md</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a4050b47426e20804f0b250a4103dc15a392b2f5-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD]]></video:title><video:description><![CDATA[EMR inboxes and insurance peer-to-peer calls are pulling clinicians away from patients, a growing concern reflected across CHEST 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407144745112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/discharge-checklist-targets-copd-readmissions-reyleen-loreto-md</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c38196e3abc8888d7d9470f657036fc8e56cda4d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Discharge Checklist Targets COPD Readmissions: Reyleen Loreto, MD]]></video:title><video:description><![CDATA[A COPD discharge checklist and navigator improved readmissions without lengthening hospital stays or increasing emergency department revisits.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407146874112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ethically-sound-care-starts-before-the-icu-nneka-sederstrom-phd</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/bd5a216e037269eaaa664ff20a41e18c030ccf9d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Ethically Sound Care Starts Before the ICU: Nneka Sederstrom, PhD]]></video:title><video:description><![CDATA[Early goals-of-care talks, ethics consults, and upstream planning can help ICU teams deliver care that matches what patients actually want.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407147137112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/expanding-bite-therapy-beyond-major-cities-wade-iams-md-msci</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/aa6b5ec93b09d5ed0462543eb5756be291d67376-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Expanding BiTE Therapy Beyond Major Cities: Wade Iams, MD, MSCI]]></video:title><video:description><![CDATA[Tennessee Oncology's Wade Iams, MD, MSCI, discusses staffing and tocilizumab access as barriers to expanding BiTE therapy and the costs of cell therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406542916112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pharmacist-triage-trends-in-attr-cm-care-namarta-kalia-pharmd</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/09527f1033830fbcf98e1605c00b02b65e2fd3a2-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Pharmacist Triage Trends in ATTR-CM Care: Namarta Kalia, PharmD ]]></video:title><video:description><![CDATA[Most specialty pharmacist interventions were routine refill and adherence touchpoints, with symptom trends driving higher-stakes provider escalations.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406981873112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/mm-infection-risk-and-bridging-therapy-mateo-mejia-saldarriaga-md</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c0b0311f60dc3687912ecbefca718ba21cf3ad21-1200x640.png</video:thumbnail_loc><video:title><![CDATA[MM Infection Risk and Bridging Therapy: Mateo Mejia Saldarriaga, MD]]></video:title><video:description><![CDATA[Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why IVIG, infection monitoring, and deeper bridging responses matter with myeloma immunotherapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406130637112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/optimizing-asthma-adherence-inhaler-technique-cost-and-team-based-care</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Optimizing Asthma Adherence: Inhaler Technique, Cost, and Team-Based Care]]></video:title><video:description><![CDATA[Adherence depends on clear explanation, reliable inhaler technique, and affordable medication, and gaps in any one of these can quietly erode the benefit of an effective treatment plan.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406426025112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vitiligo-pathogenesis-how-autoimmunity-targets-the-melanocyte</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Vitiligo Pathogenesis: How Autoimmunity Targets the Melanocyte]]></video:title><video:description><![CDATA[Vitiligo begins with oxidative stress and ends with CD8-positive T cells destroying melanocytes that cannot easily regenerate. Dr. Hamzavi maps the autoimmune cascade and the disease associations clinicians should watch for.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406038503112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/payer-strategies-for-earlier-ckd-screening-and-identification</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Payer Strategies for Earlier CKD Screening and Identification]]></video:title><video:description><![CDATA[Screening alone is not the finish line. Dr. Haumschild explains why quality measures should track whether early CKD identification actually leads to kidney-protective therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406766833112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vitiligo-prevalence-and-why-it-isn-t-cosmetic</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Vitiligo Prevalence and Why It Isn't Cosmetic]]></video:title><video:description><![CDATA[Vitiligo affects up to two percent of the population worldwide, yet payers and patients alike still misread it as cosmetic. Dr. Desai explains the autoimmune biology, systemic comorbidities, and diagnostic pitfalls that argue otherwise.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406039296112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/setting-realistic-asthma-treatment-goals-across-diverse-patient-populations</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Setting Realistic Asthma Treatment Goals Across Diverse Patient Populations]]></video:title><video:description><![CDATA[Whether the goal is remission or simply fewer exacerbations depends heavily on the population served, and repeated steroid bursts quickly accumulate into lasting harm.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406427127112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/generic-sglt2-inhibitors-and-interpreting-divergent-ckd-trial-data</loc><video:video><video:publication_date>2026-10-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Generic SGLT2 Inhibitors and Interpreting Divergent CKD Trial Data]]></video:title><video:description><![CDATA[As generics reach the SGLT2 class, payers must separate genuine cost opportunity from clinical disruption, and resist reducing two very different CKD trials to a single number.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406767521112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rising-costs-drive-patients-to-charity-aid-as-donations-fall-tiara-green</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c2d1a783e0b6dc9367b267013ef3c0a2fe5cdb25-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rising Costs Drive Patients to Charity Aid as Donations Fall: Tiara Green]]></video:title><video:description><![CDATA[Tiara Green of Accessia Health says demand for charitable patient assistance is outpacing donations as inflation and Part D changes strain patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=undefined</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/multidisciplinary-rounds-catch-overlooked-icu-devices-pooja-roy-md</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0b3088da1bc4b416b4279d2a7b015f3e7c78561f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Multidisciplinary Rounds Catch Overlooked ICU Devices: Pooja Roy, MD]]></video:title><video:description><![CDATA[Charge nurse–led multidisciplinary rounds caught ICU lines and catheters due for removal that academic teaching rounds often missed, said Pooja Roy, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407095039112 </video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/delayed-access-to-care-drives-late-stage-icu-cases-adan-mora-md</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/dc2e690f25c7b2f468f4d78e03def463e63c39ac-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Delayed Access to Care Drives Late-Stage ICU Cases: Adan Mora, MD]]></video:title><video:description><![CDATA[Limited access to care means safety-net ICUs see advanced disease and poorer outcomes, while bias and social media add new challenges to care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId= 6407093161112 </video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pulmonologists-can-close-lung-cancer-testing-gaps-eric-k-singhi-md</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9536ca5a00352e83017552369c037efbf28ba01d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Pulmonologists Can Close Lung Cancer Testing Gaps: Eric K. Singhi, MD]]></video:title><video:description><![CDATA[Pulmonologists play a key role in comprehensive biomarker testing, helping more patients with lung cancer access precise targeted therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407094454112 </video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ai-payment-policy-top-the-agenda-at-amcp-nexus-2026-susan-cantrell</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/db7577f70b8cddac680b8553756f8332e64e9d46-1200x640.png</video:thumbnail_loc><video:title><![CDATA[AI, Payment Policy Top the Agenda at AMCP Nexus 2026: Susan Cantrell]]></video:title><video:description><![CDATA[Managed care pharmacy leaders will gather at AMCP Nexus 2026 to discuss safe AI adoption, evolving drug pricing policy, and practical solutions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407052992112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/prerna-mewawalla-md-on-rethinking-indefinite-myeloma-maintenance</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6133e357a85f6aa2fa1d6dae0837e8f88e02361d-1200x627.png</video:thumbnail_loc><video:title><![CDATA[Prerna Mewawalla, MD, on Rethinking Indefinite Myeloma Maintenance]]></video:title><video:description><![CDATA[Recent ENDURANCE data support 2-year lenalidomide maintenance in standard-risk multiple myeloma and individualize when to stop.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407083858112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/writing-an-ai-playbook-for-oncology-practices-larry-bilbrey</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/12b1a09eba9c87040bbc05d90869695f33e7b02b-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Writing an AI Playbook for Oncology Practices: Larry Bilbrey]]></video:title><video:description><![CDATA[OneOncology's Larry Bilbrey explains how to guide practices on AI without endorsing products and why technology gaps outweigh workflow problems.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406494845112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/today-s-iv-antibiotic-options-for-complicated-uti-strengths-and-limitations</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Today's IV Antibiotic Options for Complicated UTI: Strengths and Limitations]]></video:title><video:description><![CDATA[Third-generation cephalosporins and aminoglycosides anchor today's intravenous options for complicated UTI, but rising extended-spectrum beta-lactamase rates and an outdated assumption that intravenous therapy requires hospitalization both limit how effectively clinicians can use them.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636064112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/barriers-to-implementing-new-complicated-uti-treatment-guidelines</loc><video:video><video:publication_date>2026-10-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Barriers to Implementing New Complicated UTI Treatment Guidelines]]></video:title><video:description><![CDATA[Guideline-concordant care runs into real-world friction: persistent overtreatment of asymptomatic bacteriuria, unfamiliar local antibiogram data, and clinician discomfort with shorter courses all complicate the path from published recommendation to bedside practice.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636653112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ai-moves-from-evaluation-to-implementation-at-aao-2026</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/30ee9eddf3fb2557909793a5c54ed8754dce5e37-1200x720.png</video:thumbnail_loc><video:title><![CDATA[AI Moves From Evaluation to Implementation at AAO 2026]]></video:title><video:description><![CDATA[Experts highlight AI adoption, sustained-release glaucoma therapies, and concerns about Medicare payment and rural access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406967665112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pbm-reform-and-supportive-care-needs-nicolas-ferreyros</loc><video:video><video:publication_date>2026-10-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/be468de28e30fb0cb17b8447126b9762b4523ce9-1200x640.png</video:thumbnail_loc><video:title><![CDATA[PBM Reform and Supportive Care Needs: Nicolas Ferreyros]]></video:title><video:description><![CDATA[COA's Nicolas Ferreyros discusses next steps for PBM reform, funding for supportive cancer services, and a hopeful outlook for community oncology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406488131112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/closing-the-gap-underused-consolidation-immunotherapy-in-limited-stage-sclc</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[Closing the Gap: Underused Consolidation Immunotherapy in Limited-Stage SCLC]]></video:title><video:description><![CDATA[Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406923732112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-adriatic-trial-consolidation-immunotherapy-in-limited-stage-sclc</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[The ADRIATIC Trial: Consolidation Immunotherapy in Limited-Stage SCLC]]></video:title><video:description><![CDATA[The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406924201112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/trispecifics-may-widen-myeloma-access-beth-faiman-phd-msn</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ff3d923942c7f17659651f0959557fb4af8de296-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Trispecifics May Widen Myeloma Access: Beth Faiman, PhD, MSN]]></video:title><video:description><![CDATA[Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406374884112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cardioembolic-stroke-severity-disability-mortality-and-recurrence-risk-in-afib</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/af8984d900205622fc3c585e916039ebe463bf9e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Cardioembolic Stroke Severity: Disability, Mortality, and Recurrence Risk in AFib]]></video:title><video:description><![CDATA[Cardioembolic stroke produces more severe strokes, greater disability, higher mortality, and frequent recurrence than other subtypes. Dr. Barnes reviews the outcome data that make prevention a clinical priority.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406972700112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hs-patient-journey-clinical-emotional-and-economic-burden</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[HS Patient Journey: Clinical, Emotional, and Economic Burden]]></video:title><video:description><![CDATA[A teenager's first abscess can start a years-long cycle of misdiagnosis, shame, and fragmented care. Dr. Lev-Tov traces how untreated HS derails lives and strains both families and the healthcare system.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406544098112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aml-risk-stratification-and-fitness-assessment-eln-systems-and-objective-criteria</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[AML Risk Stratification and Fitness Assessment: ELN Systems and Objective Criteria]]></video:title><video:description><![CDATA[Separate risk systems now guide intensive and lower-intensity AML therapy, and objective fitness criteria are replacing the eyeball test in deciding which patients should receive which approach.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406364557112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hs-pathogenesis-genetics-friction-microbiome-and-hormonal-drivers</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[HS Pathogenesis: Genetics, Friction, Microbiome, and Hormonal Drivers]]></video:title><video:description><![CDATA[HS is far more common than most clinicians realize, and its origins are multifactorial. Understanding genetic, mechanical, microbial, and hormonal contributors gives clinicians a practical foundation for designing treatment plans.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406544482112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cardioembolic-stroke-in-afib-defining-the-subtype-and-its-mechanism</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/af8984d900205622fc3c585e916039ebe463bf9e-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Cardioembolic Stroke in AFib: Defining the Subtype and Its Mechanism]]></video:title><video:description><![CDATA[Welcome back to another AJMC Insights series. In "Cardioembolic Stroke in AFib: Defining the Subtype and Its Mechanism," Dr. Barnes joins us to open the series on cardioembolic stroke in atrial fibrillation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406971824112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/understanding-aml-pathophysiology-presentation-and-diagnostic-workup</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Understanding AML: Pathophysiology, Presentation, and Diagnostic Workup]]></video:title><video:description><![CDATA[Acute myeloid leukemia arises from stem cell mutations and clonal expansion, and while diagnosis is rarely in doubt, genetic testing now shapes every treatment decision that follows.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406362794112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/future-access-strategies-in-retinal-vascular-diseases</loc><video:video><video:publication_date>2026-10-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f33965e0a439332727859f788da4d901cb4942aa-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Future Access Strategies in Retinal Vascular Diseases]]></video:title><video:description><![CDATA[Payer step therapy and formulary limits reshape anti‑VEGF care—often raising long‑term costs and risking outcomes without doctor–payer alignment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396165382112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/payers-can-help-survivors-thrive-after-treatment-bhavana-bhatnagar-do</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f4b3a7ba55e7a868ace9d8655073be98d6d15d7c-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Payers Can Help Survivors Thrive After Treatment: Bhavana Bhatnagar, DO]]></video:title><video:description><![CDATA[Bhavana Bhatnagar, DO, says payer support for social needs, registries, and survivorship care can help patients access therapy and thrive.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406855920112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/keeping-physicians-in-charge-of-oncology-ai-johnetta-blakely-md-ms</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/029ad7712ef00ff7c9c22a0cbf63c9c8a12047de-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Keeping Physicians in Charge of Oncology AI: Johnetta Blakely, MD, MS]]></video:title><video:description><![CDATA[Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406554452112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/separating-cost-from-cancer-pathways-edward-arrowsmith-md-mph</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2f8e00d3e89a54e48da9ef0d587123133d0e0dd0-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Separating Cost From Cancer Pathways: Edward Arrowsmith, MD, MPH]]></video:title><video:description><![CDATA[OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406314302112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/lems-therapy-access-candidate-selection-and-nccn-guideline-support</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[LEMS Therapy Access: Candidate Selection and NCCN Guideline Support]]></video:title><video:description><![CDATA[With amifampridine now written into the 2026 NCCN guidelines as the first LEMS-specific therapy, documentation and candidate selection carry new weight for securing coverage.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635296112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aatd-economic-burden-costs-comorbidities-and-total-cost-of-care</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[AATD Economic Burden: Costs, Comorbidities, and Total Cost of Care]]></video:title><video:description><![CDATA[Cost data in AATD depend heavily on how patients are identified. Augmentation therapy adds a substantial burden, yet survival benefit and comorbidity management complicate any simple cost comparison for payers.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746375112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/second-meta-analysis-reveals-differences-among-mdd-add-on-therapies</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/fd4287878e1ed18857995e5614198afcc8d2311f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Second Meta-Analysis Reveals Differences Among MDD Add-On Therapies]]></video:title><video:description><![CDATA[An independently conducted meta-analysis confirms similar efficacy but surfaces a notable acceptability gap, underscoring why shared decision-making and patient preference remain central to prescribing.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405499415112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/building-a-primary-care-pathway-to-aatd-testing</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Building a Primary Care Pathway to AATD Testing]]></video:title><video:description><![CDATA[Clinicians cannot be expected to remember every rare disease. Default order sets, testing tied to pulmonary function results, and standardized genotyping can make AATD testing the easy choice rather than an added burden.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405747059112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/lems-treatment-mechanisms-immunosuppression-plasma-exchange-and-potassium-channel-blockade</loc><video:video><video:publication_date>2026-10-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[LEMS Treatment Mechanisms: Immunosuppression, Plasma Exchange, and Potassium Channel Blockade]]></video:title><video:description><![CDATA[Traditional LEMS therapies work by dampening the autoantibody response, while a newer potassium channel blocker takes a faster, more direct path to restoring neuromuscular signaling.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635885112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/lasers-must-treat-skin-biology-not-color-eliot-f-battle-md</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6b2d9f910a593f12c126f17b7a4151b763655dcd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Lasers Must Treat Skin Biology, Not Color: Eliot F. Battle, MD]]></video:title><video:description><![CDATA[Eliot F. Battle, MD, says safe laser treatment in skin of color depends on age, genetics, and inflammation, not Fitzpatrick skin type alone.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406773674112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/closing-the-gap-why-sglt2-inhibitors-remain-underused</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Closing the Gap: Why SGLT2 Inhibitors Remain Underused]]></video:title><video:description><![CDATA[Fragmented care, siloed specialties, and outdated assumptions about glucose-only benefit are quietly keeping eligible patients off guideline-directed cardiorenal therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406768678112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sglt2-inhibitors-cardiorenal-expansion-reshaping-formulary-strategy</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[SGLT2 Inhibitors' Cardiorenal Expansion Reshaping Formulary Strategy]]></video:title><video:description><![CDATA[SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406769058112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/out-of-pocket-costs-and-drug-shortages-wade-iams-md-msci</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/aa6b5ec93b09d5ed0462543eb5756be291d67376-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Out-of-Pocket Costs and Drug Shortages: Wade Iams, MD, MSCI]]></video:title><video:description><![CDATA[Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406544693112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/navigating-zidesamtinib-safety-sequencing-in-ros1-nsclc</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0651af801c4edd979c6845b1b3227694a538c828-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Navigating Zidesamtinib Safety, Sequencing in ROS1+ NSCLC]]></video:title><video:description><![CDATA[Zidesamtinib offers better tolerability in ROS1-positive NSCLC, but adverse effects still need monitoring, and optimal sequencing remains unclear.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406305490112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ira-fix-needed-to-protect-community-oncology-nicolas-ferreyros</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/50b00e702e9b375cb6ac090c684777df34b0c938-1200x640.png</video:thumbnail_loc><video:title><![CDATA[IRA Fix Needed to Protect Community Oncology: Nicolas Ferreyros]]></video:title><video:description><![CDATA[Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406434902112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/asthma-remission-goals-and-where-biologic-adherence-breaks-down</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Asthma Remission Goals and Where Biologic Adherence Breaks Down]]></video:title><video:description><![CDATA[Current biologics halve exacerbations but achieve remission in a minority of patients, and adherence often falters before therapy begins or around the 6-month mark.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406426229112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/biologic-value-in-asthma-oral-steroid-toxicity-and-prior-authorization</loc><video:video><video:publication_date>2026-10-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Biologic Value in Asthma: Oral Steroid Toxicity and Prior Authorization]]></video:title><video:description><![CDATA[Biologics can offset their acquisition cost by preventing exacerbations and cumulative steroid toxicity, yet billing structures and prior authorization continue to delay patients who need treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406427799112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vyd2311-shift-from-iv-to-im-could-widen-access-michael-mina-md-phd</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/408acf5774c29b9f09502c1f5b38ec709aa30120-1200x640.png</video:thumbnail_loc><video:title><![CDATA[VYD2311 Shift From IV to IM Could Widen Access: Michael Mina, MD, PhD]]></video:title><video:description><![CDATA[Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that could expand access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406431288112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/less-intensive-aml-regimen-offers-a-better-journey-amir-fathi-md</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2e975b8ce7fbe9511e196650223c0d0ba7a31eab-1200x627.png</video:thumbnail_loc><video:title><![CDATA[Less-Intensive AML Regimen Offers a Better Journey: Amir Fathi, MD]]></video:title><video:description><![CDATA[Fathi, of Mass General Brigham Cancer Institute, says PARADIGM trial data support azacitidine-venetoclax for induction-eligible patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406708566112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-calling-vkdb-a-stroke-changes-parents-minds-on-vitamin-k</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3ae9fd0410323aab837b28eba2adb850256b3ddd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[How Calling VKDB a Stroke Changes Parents' Minds on Vitamin K]]></video:title><video:description><![CDATA[Joanna Parga-Belinkie, MD, explains how framing VKDB as a stroke and documenting refusals helps her counsel parents on vitamin K.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406423115112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nci-trial-underfunding-limits-site-enrollment-cathy-eng-md-facp-fasco</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6dbe7b4ea9d0bb25e9e659d8b2073abfc5048359-1200x640.png</video:thumbnail_loc><video:title><![CDATA[NCI Trial Underfunding Limits Site Enrollment: Cathy Eng, MD, FACP, FASCO]]></video:title><video:description><![CDATA[Cathy Eng, MD, says flat funding for NCI-sponsored trials discourages site participation and slows data, despite their importance.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405969194112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/step-therapy-can-disrupt-cancer-treatment-alyssa-schatz-drph-msw</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1c79d60bac2a3d46988146b0fb233a77c930f965-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Step Therapy Can Disrupt Cancer Treatment: Alyssa Schatz, DrPH, MSW]]></video:title><video:description><![CDATA[Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406555583112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rusfertide-keeps-working-where-hydroxyurea-fades-andrew-kuykendall-md</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a2f7db19d5842f456e6e4506dd9e402ce1bf3dea-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD]]></video:title><video:description><![CDATA[Moffitt’s Andrew Kuykenda, MD, lead VERIFY trial investigator, says rusfertide offers durable response and manageable safety.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406560704112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/putting-an-roi-on-ai-in-community-oncology-larry-bilbrey</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/12b1a09eba9c87040bbc05d90869695f33e7b02b-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Putting an ROI on AI in Community Oncology: Larry Bilbrey]]></video:title><video:description><![CDATA[OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406492887112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-ai-is-making-retina-practices-more-efficient-aaron-lee-md-msci</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5b01eb05273e102d1f856dc9784b1bba168e4002-1200x640.png</video:thumbnail_loc><video:title><![CDATA[How AI Is Making Retina Practices More Efficient: Aaron Lee, MD, MSCI]]></video:title><video:description><![CDATA[AI tools are streamlining retina practice, but adoption depends on fitting them into real-world workflows.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406690919112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/on-body-isatuximab-eases-myeloma-care-mateo-mejia-saldarriaga-md</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c0b0311f60dc3687912ecbefca718ba21cf3ad21-1200x640.png</video:thumbnail_loc><video:title><![CDATA[On-Body Isatuximab Eases Myeloma Care: Mateo Mejia Saldarriaga, MD]]></video:title><video:description><![CDATA[Weill Cornell's Mateo Mejia Saldarriaga, MD, discusses patient preference for on-body isatuximab and how to sequence CAR T and bispecifics in myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406129569112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-term-vision-after-cataract-surgery-in-amd-helia-ashourizadeh-md</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fc1567d87aa4df031e135cae434f2fc4a95a877-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Long-Term Vision After Cataract Surgery in AMD: Helia Ashourizadeh, MD]]></video:title><video:description><![CDATA[Cataract surgery improved vision across all AMD stages, but patients with advanced dry AMD lost their gains by about 30 months.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406665191112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/making-the-case-for-early-iv-to-oral-transition-in-complicated-uti</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Making the Case for Early IV-to-Oral Transition in Complicated UTI]]></video:title><video:description><![CDATA[Stepping down from intravenous to oral therapy promises faster discharge and lower environmental cost, but only when the oral agent achieves true systemic exposure, a distinction that also reshapes how clinicians define refractory cases.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635768112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-idsa-guideline-s-four-step-antibiotic-selection-framework</loc><video:video><video:publication_date>2026-10-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The IDSA Guideline's Four-Step Antibiotic Selection Framework]]></video:title><video:description><![CDATA[A structured four-step framework, weighing severity, resistance risk, safety, and local antibiogram data, gives clinicians a repeatable way to choose empiric therapy, one the panel notes converges independently across two major complicated UTI guidelines.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635666112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bim-iol-lowers-iop-35-ends-drops-for-most-patients-fiaz-zaman-md-facs</loc><video:video><video:publication_date>2026-10-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d2ea7356c120765a343dec9c960226c3519fbdc4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[BIM-IOL Lowers IOP 35%, Ends Drops for Most Patients: Fiaz Zaman, MD]]></video:title><video:description><![CDATA[New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406651129112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/a-new-mechanism-for-dme-in-the-brunello-trial-donald-j-d-amico-md</loc><video:video><video:publication_date>2026-10-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/33f1dd42083461de60609511af21dfb7fba01f8b-1200x640.png</video:thumbnail_loc><video:title><![CDATA[A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD]]></video:title><video:description><![CDATA[In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406634730112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/closing-the-gaps-in-ocular-emergency-care-james-d-auran-md</loc><video:video><video:publication_date>2026-10-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/77fe95f92cbc31db7c00c749ea2d78976ac8bfbb-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Closing the Gaps in Ocular Emergency Care: James D. Auran, MD]]></video:title><video:description><![CDATA[Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the country.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406616011112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/using-ai-to-advance-equity-in-eye-care-grayson-w-armstrong-md-mph</loc><video:video><video:publication_date>2026-10-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2649afc77a53af6bc894344e5974b51a88e77701-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Using AI to Advance Equity in Eye Care: Grayson W. Armstrong, MD, MPH]]></video:title><video:description><![CDATA[Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406616574112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pairing-vyd2311-with-mrna-covid-19-vaccines-michael-mina-md-phd</loc><video:video><video:publication_date>2026-10-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/408acf5774c29b9f09502c1f5b38ec709aa30120-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD]]></video:title><video:description><![CDATA[Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406429809112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nei-director-highlights-pediatric-advances-ai-s-promise-in-eye-care</loc><video:video><video:publication_date>2026-10-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/689b7b4bacb2b540a96fae7fb53b82069cb24e76-1200x640.png</video:thumbnail_loc><video:title><![CDATA[NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care]]></video:title><video:description><![CDATA[The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406592859112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/kerry-rogers-md-weighs-car-t-against-bispecifics-in-cll</loc><video:video><video:publication_date>2026-10-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/127f2dcd308907341a216c7d6bd91ca3605bf48f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Kerry Rogers, MD, Weighs CAR T Against Bispecifics in CLL]]></video:title><video:description><![CDATA[Duration of benefit "has to be part of the discussion," emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406494902112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/community-oncology-delivers-strong-outcomes-nicolas-ferreyros</loc><video:video><video:publication_date>2026-10-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/be468de28e30fb0cb17b8447126b9762b4523ce9-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Community Oncology Delivers Strong Outcomes: Nicolas Ferreyros]]></video:title><video:description><![CDATA[COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406489700112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/early-onset-braf-patients-need-faster-treatment-cathy-eng-md-facp-fasco</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6dbe7b4ea9d0bb25e9e659d8b2073abfc5048359-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Early-Onset BRAF Patients Need Faster Treatment: Cathy Eng, MD, FACP, FASCO]]></video:title><video:description><![CDATA[Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405970524112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/keeping-patients-on-multiple-myeloma-bispecifics-beth-faiman-phd</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ff3d923942c7f17659651f0959557fb4af8de296-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Keeping Patients on Multiple Myeloma Bispecifics: Beth Faiman, PhD]]></video:title><video:description><![CDATA[Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406373915112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vitamin-k-shot-refusals-how-neonatologists-counter-misinformation</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3ae9fd0410323aab837b28eba2adb850256b3ddd-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Vitamin K Shot Refusals: How Neonatologists Counter Misinformation]]></video:title><video:description><![CDATA[Joanna Parga-Belinkie, MD, of CHOP explains how she tailors counseling to address vitamin K shot misinformation and VKDB risks.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406425463112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/physician-choice-and-step-therapy-in-retinal-vascular-diseases</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f33965e0a439332727859f788da4d901cb4942aa-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Physician Choice and Step Therapy in Retinal Vascular Diseases]]></video:title><video:description><![CDATA[Experts question prior authorization for anti-VEGF retina drugs, urging outcome-based reviews and payer-physician dialogue to cut waste and costs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396163928112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/role-of-prior-authorization-in-accessing-anti-vegf-therapies-in-retinal-vascular-diseases</loc><video:video><video:publication_date>2026-10-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f33965e0a439332727859f788da4d901cb4942aa-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Role of Prior Authorization in Accessing Anti-VEGF Therapies in Retinal Vascular Diseases]]></video:title><video:description><![CDATA[Open-access anti‑VEGF choices cut delays in AMD, DME and RVO care, urging payer-physician collaboration for sustainable costs and better vision.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6396165279112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/patient-voice-shapes-oncology-pathways-edward-arrowsmith-md-mph</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2f8e00d3e89a54e48da9ef0d587123133d0e0dd0-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Patient Voice Shapes Oncology Pathways: Edward Arrowsmith, MD, MPH]]></video:title><video:description><![CDATA[OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how patient-reported outcomes and national disease groups can make cancer pathways more dynamic.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406313241112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/new-data-spur-reconsidering-transplant-in-younger-all-patients</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c5d69fcf5d5618e471613b319e0440fd0f0cee7a-1200x640.png</video:thumbnail_loc><video:title><![CDATA[New Data Spur Reconsidering Transplant in Younger ALL Patients]]></video:title><video:description><![CDATA[Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406375797112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aatd-genotypes-aat-levels-and-lung-versus-liver-disease-risk</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[AATD Genotypes, AAT Levels, and Lung Versus Liver Disease Risk]]></video:title><video:description><![CDATA[The same AAT level can mean very different protease burdens in two patients. Severe deficiency drives the highest risk, yet carriers and unusual alleles complicate any simple relationship between numbers and disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746374112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ordering-vgcc-testing-and-navigating-nccn-guidelines-for-lems</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Ordering VGCC Testing and Navigating NCCN Guidelines for LEMS]]></video:title><video:description><![CDATA[Getting a voltage-gated calcium channel antibody test ordered correctly takes attention to detail, and NCCN's explicit recommendation is reshaping how quickly clinicians act on it.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405635414112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/lems-natural-history-recognizing-symptoms-before-a-small-cell-diagnosis</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/260a8cea7468c0ee7968a11d1526ce211d4f8ed1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[LEMS Natural History: Recognizing Symptoms Before a Small Cell Diagnosis]]></video:title><video:description><![CDATA[LEMS symptoms frequently predate the small cell lung cancer diagnosis itself, and knowing which symptom patterns to watch for can shorten the path to recognition.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636776112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/first-network-meta-analysis-compares-efficacy-and-safety-of-mdd-adjunctive-therapies</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/fd4287878e1ed18857995e5614198afcc8d2311f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[First Network Meta-Analysis Compares Efficacy and Safety of MDD Adjunctive Therapies]]></video:title><video:description><![CDATA[The study's own senior author walks through its design, then reveals meaningful differences in weight gain, akathisia, and sedation risk that should inform how clinicians and payers evaluate these agents.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405499134112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aatd-is-not-just-copd-why-testing-rates-stay-low</loc><video:video><video:publication_date>2026-10-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[AATD Is Not Just COPD: Why Testing Rates Stay Low]]></video:title><video:description><![CDATA[Decades of guidelines have recommended testing every patient with COPD, yet testing remains rare. The panel examines who gets missed, why clinicians believe they can spot AATD, and what health plans can do.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746183112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/getting-new-cancer-drugs-chairside-mitchell-blewett-pharmd-ms</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/adfe6a434d3b1b77060911852e6d395674685635-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Getting New Cancer Drugs Chairside: Mitchell Blewett, PharmD, MS]]></video:title><video:description><![CDATA[Mitchell Blewett, PharmD, MS, of Cleveland Clinic, explains why formulary approval is only the midpoint before a new oncology drug reaches patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406130665112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/where-zidesamtinib-fits-in-the-ros1-nsclc-treatment-landscape</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0651af801c4edd979c6845b1b3227694a538c828-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Where Zidesamtinib Fits in the ROS1+ NSCLC Treatment Landscape]]></video:title><video:description><![CDATA[Zidesamtinib offers a new treatment option for previously treated ROS1-positive NSCLC, with rapid, durable responses and strong brain activity.
]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406303255112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/severe-asthma-exacerbations-indirect-costs-and-when-to-escalate-therapy</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Severe Asthma Exacerbations, Indirect Costs, and When to Escalate Therapy ]]></video:title><video:description><![CDATA[Asthma costs extend well beyond the emergency department, into lost schooling, reduced earning potential, and steroid harm, which sharpens the case for recognizing uncontrolled disease and escalating care promptly. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406362128112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/type-2-inflammation-and-the-economic-cost-of-severe-asthma</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Type 2 Inflammation and the Economic Cost of Severe Asthma]]></video:title><video:description><![CDATA[Most patients with asthma carry a type 2 inflammatory signature, and the sickest fifth of them account for the bulk of an $80 billion annual burden.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406361263112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sglt2-inhibitors-practical-guidance-for-clinicians-and-formularies</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5f2a65bee837a301cc9367469bdb7cf41aa2795b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[SGLT2 Inhibitors: Practical Guidance for Clinicians and Formularies]]></video:title><video:description><![CDATA[Clinicians who understand the SGLT2 inhibitor trial evidence are positioned to champion appropriate use on formulary committees, matching real-world patients to the populations the pivotal trials actually studied.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6404778193112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/closing-screening-gaps-for-cardio-kidney-metabolic-disease</loc><video:video><video:publication_date>2026-10-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5f2a65bee837a301cc9367469bdb7cf41aa2795b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Closing Screening Gaps for Cardio-Kidney-Metabolic Disease]]></video:title><video:description><![CDATA[Specialty silos leave a large population of at-risk patients undiagnosed for adjacent cardio-kidney-metabolic conditions, and aligning incentives around earlier screening could meaningfully change patients' long-term risk trajectories and downstream costs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6404777586112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/copd-biologics-expand-options-as-biomarker-rules-limit-access</loc><video:video><video:publication_date>2026-10-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0f05c369dc2904a97c2b5b4458d6e70ae3947c69-1200x640.png</video:thumbnail_loc><video:title><![CDATA[COPD Biologics Expand Options as Biomarker Rules Limit Access]]></video:title><video:description><![CDATA[Geoffrey Chupp, MD, explains how IL-5 and IL-4Rα biologics are reshaping COPD care and why eosinophil requirements still limit access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406049000112</video:player_loc></video:video></url></urlset>